Literature DB >> 9045959

Increased expression of CD44 variants in differentiated thyroid cancers.

T Takano1, H Sumizaki, K Nakano, F Matsuzuka, K Kuma, N Amino.   

Abstract

Expression of CD44 variants in thyroid tumors was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) with a fluorescent image analyzer. Increased expression of CD44 variants compared with normal thyroid tissues was observed in most thyroid follicular tumors, especially in follicular carcinomas, poorly differentiated papillary carcinomas and some follicular adenomas. However, variants were hardly detectable in an anaplastic carcinoma. Analysis with restriction enzymes revealed that the major PCR product, consisting of variant bands, was derived from CD44E. Therefore, the expression of CD44E may be associated with the proliferation of differentiated thyroid cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9045959      PMCID: PMC5921027          DOI: 10.1111/j.1349-7006.1996.tb03139.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  17 in total

1.  The molecular biology of the human anaplastic thyroid carcinoma cell.

Authors:  N E Heldin; B Westermark
Journal:  Thyroidology       Date:  1991-12

2.  Polymerase chain reaction-based mRNA quantification using an internal standard: analysis of oncogene expression.

Authors:  R H Scheuermann; S R Bauer
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

3.  The WHO histological classification of thyroid tumors: a commentary on the second edition.

Authors:  C Hedinger; E D Williams; L H Sobin
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

4.  CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants.

Authors:  C Rodriguez; G Monges; P Rouanet; B Dutrillaux; D Lefrançois; C Theillet
Journal:  Int J Cancer       Date:  1995-10-20       Impact factor: 7.396

5.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

6.  Expression of the Hermes-1 (CD44) and ICAM-1 (CD54) molecule on the surface of thyroid cells from patients with Graves' disease.

Authors:  H Fukazawa; K Yoshida; R Ichinohasama; T Sawai; Y Hiromatsu; K Mori; K Kikuchi; Y Aizawa; K Abe; J R Wall
Journal:  Thyroid       Date:  1993       Impact factor: 6.568

7.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports.

Authors:  Z Guo; R A Guilfoyle; A J Thiel; R Wang; L M Smith
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

9.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

Review 10.  CD44: the hyaluronan receptor.

Authors:  C Underhill
Journal:  J Cell Sci       Date:  1992-10       Impact factor: 5.285

View more
  2 in total

1.  Analysis of splice variants of the fibronectin gene in thyroid carcinomas by reverse transcription-polymerase chain reaction: increased expression of oncofetal fibronectin mRNA in papillary carcinomas is not caused by the alternation in splicing.

Authors:  T Takano; F Matsuzuka; G Liu; A Miyauchi; T Yokozawa; K Kuma; N Amino
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 2.  Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy.

Authors:  Mingxu Guan; Yanping Ma; Sahil Rajesh Shah; Gaetano Romano
Journal:  Oncolytic Virother       Date:  2016-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.